Sequential PD-1/PD-L1 Inhibitor and LENvatinib in Transitional Liver Cell Tumors TLCT and Refractory Hepatoblastoma for Young Adolescent and Pediatric Participants After Chemotherapy a Cohort Study
Latest Information Update: 07 Mar 2024
At a glance
- Drugs Camrelizumab (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Sintilimab (Primary)
- Indications Hepatoblastoma; Liver cancer
- Focus Therapeutic Use
- Acronyms sPLENTY-pc
Most Recent Events
- 18 Apr 2022 New trial record